WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event. About Apelli ...

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed re ...

As filed with the Securities and Exchange Commission on February 23, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 9 ...

Core Viewpoint - argenx is actively engaging in the healthcare sector by participating in conferences to discuss advancements in immunology and its commitment to treating severe autoimmune diseases [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, exploring its potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]. Event Participation - Karen Massey, the Chief Operating Officer of argenx, will participate in a fireside chat at the TD Cowen 46 Annual Healthcare Conference on March 2 at 11:50 a.m. ET [1]. - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2].

Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 price target. The analyst said there is still “plenty of time” before the Phase 3 MARITIME trial results are released, which means the “biggest source of debate” around Amgen will remain unresolved for now. The firm also note ...

Core Viewpoint - CStone Pharmaceuticals has received a new indication approval from the UK MHRA for sugemalimab as a monotherapy for adult patients with unresectable stage III NSCLC, expanding its therapeutic applications and commercial potential globally [1][4]. Group 1: Product Approval and Indications - Sugemalimab is now approved as a monotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on 1% of tumor cells and no sensitizing EGFR mutations or ALK, ROS1 genomic aberrations [1][5]. - The approval is based on the GEMSTONE-301 study, which showed statistically significant improvement in progression-free survival (PFS) and clinically meaningful prolongation of overall survival (OS) for patients with stage III NSCLC [4]. Group 2: Market Expansion and Commercialization - Sugemalimab has become one of only two PD-(L)1 antibodies approved for stage III NSCLC in Europe since its initial EU approval in July 2024, with a commercial footprint now extending to over 60 countries and regions [2][4]. - The product has been included in multiple national reimbursement systems, indicating its recognized clinical value and pharmacoeconomic benefit [2]. Group 3: Future Development and Regulatory Strategy - CStone plans to advance regulatory filings for sugemalimab in additional indications, including gastric cancer and esophageal squamous cell carcinoma [2]. - The company has established four commercialization partnerships for sugemalimab across Europe, the Middle East, Africa, and Latin America, actively rolling out its global commercial strategy [4]. Group 4: Company Overview - CStone Pharmaceuticals, established in late 2015, focuses on the research and development of therapies for oncology and other key disease areas, having launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications [6]. - The company's pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines [6].

Core Insights - Redmile Group increased its stake in Immunome by purchasing 695,000 shares, valued at approximately $12.20 million, during the fourth quarter of 2025 [2][7] - Immunome's stock price rose to $22.69 as of February 17, 2026, reflecting a 120% increase over the past year, significantly outperforming the S&P 500's 13% gain [8][10] - The company has raised around $400 million through a share offering to fund its oncology pipeline and reported positive Phase 3 results for its drug varegacestat [7][11] Company Overview - Immunome is a clinical-stage biotechnology company focused on developing antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms [6][9] - As of February 17, 2026, Immunome's market capitalization is $2.09 billion, with a revenue of $9.68 million and a net income of -$222.74 million [4] Investment Implications - The recent buy activity by Redmile Group indicates confidence in Immunome's pipeline, suggesting it is not merely a momentum trade but a long-term investment opportunity [10] - The company's position now represents 9.05% of Redmile Group's assets under management, highlighting its significance in the portfolio [8]

Core Insights - Redmile Group increased its stake in Scholar Rock Holding Corporation by purchasing 1,316,390 shares, valued at approximately $49.37 million based on quarterly average pricing [1][2] - The quarter-end value of Redmile's position in Scholar Rock increased by $84.58 million, reflecting both the acquisition of additional shares and market price movements [2] Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies that modulate protein growth factor signaling, addressing unmet medical needs in neuromuscular, oncological, and fibrotic indications [6] - The company has a proprietary platform and is positioned to capitalize on innovative science in high-impact therapeutic areas through strategic collaborations and a focused pipeline [6] Financial Metrics - As of February 17, 2026, Scholar Rock's stock price was $46.45, with a market capitalization of $4.78 billion [4] - The company reported a net income of -$353.43 million (TTM) and a one-year price change of 25.71% [4] Investment Implications - The purchase by Redmile Group indicates a strong commitment to Scholar Rock, which now represents approximately 17% of the fund's assets under management [7][10] - Scholar Rock is expected to submit a Biologics License Application for apitegromab in spinal muscular atrophy, with a potential U.S. launch anticipated following approval this year [9] - The company had approximately $365 million in cash as of December 31, providing a runway into 2027 and reducing near-term dilution risk for investors [9] Market Performance - Scholar Rock's shares have increased by about 26% over the past year, outperforming the broader market and indicating that investors are recognizing the value of regulatory progress and pipeline depth [11] - The company is also developing additional programs, including FSHD and the SRK-439 myostatin inhibitor, which expand its potential market opportunities [11]

Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly through bispecific antibodies and antibody-drug conjugates [6] - The company has a robust pipeline and strategic partnerships with major pharmaceutical firms, providing a competitive edge in targeted oncology therapeutics [6] - As of February 17, 2026, Zymeworks has a market capitalization of $1.74 billion and reported revenue of $134.48 million with a net income of -$63.43 million [4] Recent Developments - Redmile Group significantly reduced its stake in Zymeworks by 3,214,096 shares, valued at approximately $70.10 million, as disclosed in a February 17, 2026, SEC filing [2] - The quarter-end value of Redmile's position in Zymeworks decreased by $50.35 million due to share sales and stock price movements [2] - Following the sale, Zymeworks now accounts for 0.95% of Redmile's reportable 13F assets under management (AUM) [7] Performance Metrics - Zymeworks shares were priced at $23.07 as of February 17, 2026, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 13% gain during the same period [7] - The company is eligible for up to $440 million in regulatory milestone payments tied to approvals in major markets [9] - Zymeworks ended 2025 with approximately $270.6 million in cash and marketable securities, alongside a $125 million share repurchase authorization [9] Strategic Insights - The reduction in Redmile's position is interpreted as capital recycling rather than a loss of confidence, as Zymeworks is in a transition phase balancing royalty aggregation, internal R&D, and capital returns [10] - The company continues to focus on addressing unmet medical needs in cancer treatment through licensing agreements, research collaborations, and milestone payments from strategic partners [8]

The consensus price target for VTVT has increased to $53.50, indicating growing optimism.Recent upgrade to a Zacks Rank #2 (Buy) reflects increased confidence in the company's earnings potential.Strategic partnerships and advancements in clinical trials for TTP399 and HPP737 are key drivers of positive outlook.vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company that focuses on developing oral treatments for diabetes and other diseases. The company is advancing several promising ...